INSIGHTS ON DRUG DEVELOPMENT

• Navigating Preclinical Drug Development Challenges With Lipid-Based Formulations

  Maximize the oral bioavailability of challenging small-molecule candidates and streamline the path from preclinical toxicology to clinical trials by leveraging optimized lipid-based formulations.

• Automating High-Throughput Screens Using Patient-Derived Organoids

  Many oncology drugs fail in later development stages due to inadequate predictive models. Explore how 3D cell models, like patient-derived organoids, offer a promising solution in the drug development process.

• Advancing Drug Safety And Improving R&D Productivity With The Liver-Chip S1

  Explore how the Emulate Liver-Chip S1 revolutionizes predictive toxicology by mimicking human liver biology, achieving superior sensitivity and specificity.

• Cracking Complexity: Learnings From 70+ Bispecific Antibody Programs

  The goal is practical: help development teams make early decisions that balance speed, quality, and risk and support a smoother path to the clinic.

• Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs)

  6/15/2026

  ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.

• Accelerating Clinical Development: Modern Tools In Process Chemistry

  1/23/2025

  Whether you aim to address bottlenecks or explore advanced techniques, gain a practical and forward-thinking perspective to streamline early-phase development with HTE and model-based approaches.

• Sterilization Of APIs – The Alternative: Sterile Filtration Following Aseptic Processing

  5/21/2026

  When terminal sterilization isn't an option for heat- or radiation-sensitive APIs, sterile filtration with aseptic processing protects quality. Get the technical framework.

• Improving Bioavailability Through Predictive Modeling Of Solubility Enhancement Strategies

  7/15/2026

  In silico modeling cut through formulation guesswork for a compound with 0.015 mg/mL solubility, delivering an 8× Cmax and 5× AUC improvement and Phase I progression.

• The Body As A Bioreactor – Delivering The Vision

  8/8/2026

  Making the body a bioreactor requires precise delivery to selected cells. See how lipid nanoparticles, manufacturing science, and biology are converging to overcome biological barriers and improve the targeting of advanced therapies.